DBV Technologies (NASDAQ:DBVT – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for DBV Technologies and Solid Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DBV Technologies | 1 | 0 | 4 | 0 | 2.60 |
| Solid Biosciences | 0 | 3 | 1 | 0 | 2.25 |
DBV Technologies presently has a consensus target price of $5.38, indicating a potential upside of 251.31%. Solid Biosciences has a consensus target price of $45.00, indicating a potential upside of 886.84%. Given Solid Biosciences’ higher probable upside, analysts plainly believe Solid Biosciences is more favorable than DBV Technologies.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DBV Technologies | $4.84 million | 59.52 | -$96.27 million | ($0.65) | -2.35 |
| Solid Biosciences | $8.09 million | 11.03 | -$85.98 million | ($9.99) | -0.46 |
Solid Biosciences has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
DBV Technologies has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
Institutional and Insider Ownership
18.4% of DBV Technologies shares are owned by institutional investors. 0.6% of DBV Technologies shares are owned by company insiders. Comparatively, 14.8% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares DBV Technologies and Solid Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DBV Technologies | -778.60% | -52.54% | -42.92% |
| Solid Biosciences | N/A | -48.94% | -39.96% |
Summary
Solid Biosciences beats DBV Technologies on 9 of the 14 factors compared between the two stocks.
About DBV Technologies
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
About Solid Biosciences
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo.png?v=20230126145249&h=45&w=95&zc=2){kind=logo}
